<DOC>
	<DOCNO>NCT00027599</DOCNO>
	<brief_summary>Phase II trial study effectiveness APC8015 combine bevacizumab treat patient undergone radiation therapy and/or surgery progressive prostate cancer . Biological therapy APC8015 use different way stimulate immune system stop cancer cell grow . Monoclonal antibody bevacizumab locate tumor cell kill without harm normal cell . Combining monoclonal antibody therapy biological therapy may kill cancer cell .</brief_summary>
	<brief_title>APC8015 Bevacizumab Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy APC8015 ( Provenge ) bevacizumab , term decline prostate-specific antigen ( PSA ) value effect PSA doubling time , patient progressive prostate cancer . II . Determine immune response patient treat regimen . III . Determine safety regimen patient . OUTLINE : Autologous dendritic cell ( DCs ) harvest pulsed prostatic acid phosphatase-sargramostim fusion protein produce APC8015 ( Provenge ) . Patients receive APC8015 IV 30 minute bevacizumab IV 30-60 minute day 1 . Treatment repeat every 14 day 3 course . Patients continue receive bevacizumab alone every 14 day absence disease progression unacceptable toxicity . Patients follow every month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Any T , N , M0 Received prior therapy comprise one follow regimen primary prostate cancer : External beam radiotherapy Brachytherapy without pelvic external beam radiotherapy Cryosurgery Radical prostatectomy without adjuvant salvage radiotherapy Adjuvant salvage radiotherapy radical prostatectomy allow provide follow criterion meet : PSA never great 6.0 ng/mL At least 3 month since androgen deprivation Elevated PSA ( 0.46.0 ng/mL ) increase 2 measurement take least 2 week apart No history radiological evidence current CNS disease ( e.g. , primary brain tumor , seizures control standard medical therapy , brain metastasis ) PATIENT CHARACTERISTICS : Performance status : ECOG 01 Life expectancy : At least 12 month Hematopoietic : WBC great 2,500/mm^3 Absolute neutrophil count great 1,000/mm^3 Platelet count great 100,000/mm^3 No prior bleed disorder Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) AST great 2 time ULN Hepatitis B C negative Renal : Creatinine great 2 time ULN BUN great 2 time ULN Cardiovascular : No clinically significant cardiovascular disease No New York Heart Association grade IIIV heart disease ( symptomatic congestive heart failure ) No unstable angina pectoris No serious cardiac arrhythmia require medication No uncontrolled hypertension No prior myocardial infarction No grade II great peripheral vascular disease within past year No prior deep vein thrombosis Other : Fertile patient must use effective contraception HIV HTLV I II negative No uncontrolled illness , underlie medical condition , psychiatric illness , social situation would preclude study participation No ongoing active infection No active autoimmune disease require treatment No significant traumatic injury within past 4 week No serious nonhealing wound , ulcer , bone fracture No `` currently active '' malignancy except nonmelanoma skin cancer Not `` currently active '' consider physician less 30 % risk relapse completion therapy PRIOR CONCURRENT THERAPY : Biologic therapy : No prior immunotherapy No prior antivascular endothelial growth factor therapy Chemotherapy : No prior chemotherapy Endocrine therapy : No prior hormonal therapy ( e.g. , luteinizing hormonereleasing hormone [ LHRH ] agonists antagonist , antiandrogens , estrogen , megestrol , PCSPES ) progressive disease Prior hormonal therapy adjuvant neoadjuvant set primary therapy allow least 3 month since androgen deprivation No concurrent systemic steroid therapy ( inhaled topical steroid allow ) Radiotherapy : No concurrent radiotherapy Surgery : At least 4 week since prior major surgery , include open biopsy needle biopsy liver No concurrent major surgery Other : At least 10 day since prior aspirin At least 10 day since prior oral parenteral anticoagulant except maintain patency preexist permanent indwell IV catheter No concurrent aspirin No concurrent oral parenteral anticoagulant except maintain patency preexist permanent indwell IV catheter No concurrent experimental commercial agent therapy prostate cancer</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2003</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>